Ipamorelin dosage: human and animal experiments

The human route studied

The published Ipamorelin human studies administered it intravenously, directly into a vein. The volunteer blood study characterized single infusions. The bowel-surgery trial tested treatment over a short postoperative window. Neither established an approved human dose.

Subcutaneous administration means delivery beneath the skin. That route appears in animal research and anecdotal community use, with no published human pharmacokinetic characterization in the record here. I distrust a dosing answer that omits this change of route: it removes a basic condition of the experiment while preserving the impressive-looking number.

What staff administered in the human studies

I keep these study figures separate from the prescription-only CJC-1295 and ipamorelin blend listed by Promise Peptides at mypromise.com. Its licensed U.S. clinicians prescribe the blend today after assessing the person, and they can refuse a request. Its patients must be in the United States; state rules and the particular treatment also narrow its options. The compounded blend has no FDA approval. FDA retains ipamorelin acetate in Category 2 under 503B for significant safety risks. These study doses establish no personal regimen.

Two human datasets define the studied range. In the PK/PD study, healthy male volunteers received single 15-minute IV infusions at 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg, producing dose-proportional kinetics ^[2]. In the only efficacy trial, bowel-resection patients received 0.03 mg/kg IV twice daily for up to 7 days — a regimen that missed its primary endpoint ^[3]. Both were intravenous and clinic-administered. Neither establishes a self-administration dose, and the dominant real-world route (subcutaneous) has no published human PK characterization at all ^[3].

Animal study amounts

The rat bone-growth study tested 18, 90, and 450 micrograms daily, divided into three subcutaneous injections for 15 days. These amounts describe adult female rats and the bone-growth question being tested.

The 2024 ferret study used 1–3 milligrams per kilogram intraperitoneally, into the abdominal cavity, during cisplatin-associated weight loss. A different species, route, and illness accompanied those figures.

A human regimen remains out of reach of those animal results. The amounts make sense in those experiments, with their particular species and endpoints.

These animal research doses are specific to their species and models; none establishes a human regimen.

Combination dosing and preparation

CJC-1295 Ipamorelin dosage

No controlled human dosing study has validated an amount or schedule for the pair. The 2026 primer discusses an animal muscle finding and leaves clinical dosing unknown. Community protocols are anecdotal practices, with no trial basis for choosing a personal amount.

CJC-1295 Ipamorelin 5mg: preparation

A “5mg” label states a claimed container amount. It establishes neither a clinical dose nor verified identity, purity, or sterility. Research handling notes about freeze-dried powder, heat, and refrigeration provide no validated home-preparation method. This site provides no mixing or injection instructions.

NN703 and oral absorption

The NN703 experiments concern a molecule derived from ipamorelin by structural modification. In dogs, NN703 had about 30% oral bioavailability. Ipamorelin itself has very poor oral availability.

Changing the molecule to improve absorption changes the substance being studied. The dog finding therefore supplies evidence about NN703. Human ipamorelin blood timing still comes from the intravenous volunteer study.